Candel Therapeutics Inc (CADL) Stock Price, Quote & News

Company Profile

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic,...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 916 5445

Website: www.candeltx.com

Address:

117 Kendrick Street, Suite 450, Needham, United States

GISBlaster98 Apr. 5 at 12:56 PM

$CADL What does this group think of CADL vs MAIA? Both companies going after the same markets and pressing to get their drugs through the regulatory process and get to FDA approval. I am invested in MAIA but thinking of starting a position in CADL … unfortunately ( due to cancers) the market is certainly big enough for both companies

1 · Reply

marked0ne Apr. 5 at 10:58 AM

$CADL happy easter to y‘all. Do me a favor: play alot with your eggs. I want to grab some presents this years christmas.

1 · Reply

Heap_Of_Funk Apr. 4 at 2:14 AM

$CADL sad? No not anymore. Winter blues are pretty much over now. Sun is shining and summer is coming. Nothing to be sad about

0 · Reply

pyroclast Apr. 3 at 9:48 PM

$CADL yes y e s Y E S !!!!!

0 · Reply

DiamondDog33 Apr. 3 at 9:07 PM

$CADL Moral of the story below .....ITS GETTING close TO FRUTION!!!!! besides that little bit is installments over time. Shorty trying to time when the MM will lets his foot off the ALGO ...is getting near.

1 · Reply

focafoca99 Apr. 3 at 8:28 PM

$CADL granted inducement options on 70,000 shares to five new employees at a $4.90 exercise price.

0 · Reply

drizz Apr. 3 at 6:14 PM

$CADL 12-18 months from now we will be bought for $5-$10B - possbly sooner and possibly for more!

1 · Reply

StackinTheGainz Apr. 3 at 12:50 PM

$CADL still

0 · Reply

kinosouppp Apr. 3 at 12:42 PM

$CADL still

0 · Reply

Deeconomics Apr. 3 at 10:42 AM

$CADL Dr. PPT PPT and Candel Therapeutics advisory board with a Nobel Prize winner and cancer science pioneers, as well as its board of directors that includes a CEO emeritus from Dana Farber Cancer Institute (DFCI has been involved in more then half of all FDA approved cancer drugs in the past several years) is "Smarter Then The Average Bears". Catalysts are coming soon and Candel's pipeline is amongst the best there is to prove that good can become great and great can become game changing for cancer patients and shareholders.

0 · Reply

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 17, 2026, 8:05 AM EDT - 19 days ago

Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors

Mar 12, 2026, 8:05 AM EDT - 24 days ago

Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

Mar 9, 2026, 8:05 AM EDT - 27 days ago

Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

Feb 24, 2026, 8:05 AM EST - 5 weeks ago

Candel Therapeutics to Present at TD Cowen's 46th Annual Health Care Conference in Boston

Feb 20, 2026, 4:57 AM EST - 6 weeks ago

Stock Market Today: Dow Jones, S&P 500 Futures Rise Ahead Of Q4 GDP Numbers—Grail, Candel Therapeutics, Copart In Focus

CPRT IVV SPXL SPY SSO UPRO VOO

Feb 19, 2026, 9:40 PM EST - 6 weeks ago

Candel Therapeutics Announces Pricing of Public Offering

Feb 19, 2026, 4:05 PM EST - 6 weeks ago

Candel Therapeutics Announces Proposed $100 Million Public Offering

Feb 19, 2026, 4:01 PM EST - 6 weeks ago

Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

Feb 11, 2026, 8:05 AM EST - 7 weeks ago

Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit

Nov 17, 2025, 4:05 PM EST - 4 months ago

Candel Therapeutics to Host Virtual R&D Event on December 5, 2025

Nov 13, 2025, 8:25 AM EST - 5 months ago

Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

TRIN

Nov 4, 2025, 9:00 AM EST - 5 months ago

Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors

Nov 3, 2025, 8:05 AM EST - 5 months ago

Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London

Oct 16, 2025, 8:05 AM EDT - 6 months ago

Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board

Oct 14, 2025, 8:10 AM EDT - 6 months ago

Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.

Oct 14, 2025, 8:10 AM EDT - 6 months ago

Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer

TRIN

Oct 14, 2025, 8:05 AM EDT - 6 months ago

Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine

Oct 13, 2025, 10:22 AM EDT - 6 months ago

Candel Therapeutics Has A Protracted, But Real, Timeline To Approval Now

Oct 3, 2025, 9:05 AM EDT - 6 months ago

Candel Therapeutics to Present at the SITC 2025 Annual Meeting

Sep 29, 2025, 8:05 AM EDT - 6 months ago

Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

Sep 17, 2025, 8:05 AM EDT - 7 months ago

Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

Sep 7, 2025, 10:53 AM EDT - 7 months ago

Candel Therapeutics: Potentially The Next Exciting Oncology Story

Sep 5, 2025, 12:47 PM EDT - 7 months ago

Candel Therapeutics: Oncolytic Immunotherapy Showing Broad Efficacy In Tough Tumors

Sep 2, 2025, 8:05 AM EDT - 7 months ago

Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D.

Aug 28, 2025, 8:05 AM EDT - 7 months ago

Candel Therapeutics to Participate in Upcoming Investor Conferences in September

Aug 14, 2025, 8:05 AM EDT - 8 months ago

Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Jul 30, 2025, 8:05 AM EDT - 8 months ago

Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

Jul 24, 2025, 8:05 AM EDT - 9 months ago

Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer

Jul 9, 2025, 8:05 AM EDT - 9 months ago

Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution

Jun 24, 2025, 9:05 AM EDT - 10 months ago

Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock

Jun 23, 2025, 8:05 AM EDT - 10 months ago

Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer

Jun 6, 2025, 8:05 AM EDT - 10 months ago

Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

May 28, 2025, 8:05 AM EDT - 11 months ago

Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer

May 27, 2025, 8:05 AM EDT - 11 months ago

Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation

May 22, 2025, 5:05 PM EDT - 11 months ago

Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

May 13, 2025, 8:05 AM EDT - 11 months ago

Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 6, 2025, 8:05 AM EDT - 11 months ago

Candel Therapeutics to Present at Upcoming Investor Conferences

Apr 23, 2025, 4:05 PM EDT - 1 year ago

Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

Apr 1, 2025, 8:01 AM EDT - 1 year ago

Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

Mar 26, 2025, 4:05 PM EDT - 1 year ago

Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D.

Mar 13, 2025, 4:15 PM EDT - 1 year ago

Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

Feb 25, 2025, 4:52 PM EST - 1 year ago

Candel Therapeutics: I Say Stay The Course Despite The Market's Rebuke Of Positive Pancreatic Data

Feb 25, 2025, 8:00 AM EST - 1 year ago

Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

Feb 20, 2025, 10:45 AM EST - 1 year ago

Candel Therapeutics: Entering Its Pivotal Year

Jan 13, 2025, 8:00 AM EST - 1 year ago

Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025

Jan 2, 2025, 11:46 PM EST - 1 year ago

Best-Performing Stocks Of 2024

APP BYRN DAVE INOD JANX LUNR MSTR

Dec 16, 2024, 4:01 PM EST - 1 year ago

Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

GISBlaster98 Apr. 5 at 12:56 PM

1 · Reply

marked0ne Apr. 5 at 10:58 AM

$CADL happy easter to y‘all. Do me a favor: play alot with your eggs. I want to grab some presents this years christmas.

1 · Reply

Heap_Of_Funk Apr. 4 at 2:14 AM

$CADL sad? No not anymore. Winter blues are pretty much over now. Sun is shining and summer is coming. Nothing to be sad about

0 · Reply

pyroclast Apr. 3 at 9:48 PM

$CADL yes y e s Y E S !!!!!

0 · Reply

DiamondDog33 Apr. 3 at 9:07 PM

1 · Reply

focafoca99 Apr. 3 at 8:28 PM

$CADL granted inducement options on 70,000 shares to five new employees at a $4.90 exercise price.

0 · Reply

drizz Apr. 3 at 6:14 PM

$CADL 12-18 months from now we will be bought for $5-$10B - possbly sooner and possibly for more!

1 · Reply

StackinTheGainz Apr. 3 at 12:50 PM

$CADL still

0 · Reply

kinosouppp Apr. 3 at 12:42 PM

$CADL still

0 · Reply

Deeconomics Apr. 3 at 10:42 AM

0 · Reply

DiamondDog33 Apr. 3 at 2:30 AM

$CADL First 5 close in a Month....As we approach the file the anticipators (smart money) kick 6 by June 7 by Aug/sept ....New High NovDec BUT B4 .....I need two more 4 print blocks ....next week on WAR<<<< b4 its over you know ALGO BS BID SPREADS Tape today ....there is literally no inventory to sell anymore its all algo bs ......War ends ..Big Squeeze time in the indexes.

2 · Reply

DiamondDog33 Apr. 3 at 2:03 AM

$CADL ANOTHER AFTER HOUR PAINT of 10 SHARES..... PROBABLY STU EVERY NIGHT .... CLOSE OVER THE 20 as BOLLINGER TOP EXPANDING AGAIN and 20 starting a CURL .... Lets see if it can get to 5.46 by APRIL 17< Trended Against WAR HEADLINE today ... Low< share director annual grants BFD ...and a handful for some New employees who are getting PROSTAK INTO ITS FINAL LAUNCH PAD phase

0 · Reply

DiamondDog33 Apr. 2 at 9:26 PM

$CADL if you can fill my Boat with more 4print over the next 2 weeks ..I will KISS YOU ......YOUR ALGO BID SPREADS drops on 1,2,4,6 shares are so amusing .........for my gather.

0 · Reply

stu4 Apr. 2 at 9:04 PM

$CADL $TNXP oh boo hooo @Terminator1 … You have a son by a maid as well , hahaha Another TAK loser ..and a MAGA deplorable !!!!

0 · Reply

CrollSprings Apr. 2 at 8:14 PM

$CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-announces-inducement-grants-under-nasdaq-1

1 · Reply

RetireB4FortyX Apr. 2 at 7:26 PM

$CADL CADL Stock Analysis: High Short Interest Biotech With Big Upside? Full Stock Analysis Here: https://shorturl.at/zjKLs Don't forget to follow along and sign up for our free email so you don't miss any alerts. Also make sure to check out our new discord

1 · Reply

vu_jade Apr. 2 at 6:54 PM

$CADL my average is $5.92 … And I feel great

4 · Reply

FelixH86 Apr. 2 at 6:51 PM

$CADL

0 · Reply

Kingjake26 Apr. 2 at 6:49 PM

$CAPR $CADL Great day.

1 · Reply

Musky49 Apr. 2 at 6:01 PM

$CADL Still BAF

0 · Reply

Drcando Apr. 2 at 5:20 PM

$CADL Piss poor volume for now Let's see how it is later in the quarter an 3rd quarter 🐂🐂🐂

0 · Reply

Stocksprofessional Apr. 2 at 4:24 PM

$CADL Wishing all the longs a very happy Easter 🐣 Stay patient, trust your conviction, and ignore the noise—the strong hands always win. Green days ahead 📈

1 · Reply

Market Cap	366.24M
Revenue (ttm)	0.00
Net Income (ttm)	-38.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.91

Volume	910,300
Avg Vol	1,200,142
Day's Range	N/A - N/A
Shares Out	73.25M
Stochastic %K	78%
Beta	-0.81
Analysts	Strong Sell
Price Target	$18.88